Before we begin, Tom will apprise you of our potential to make forward-looking statements. Tom?

Tom Dubin

Thanks, Lenny. During this call, we may make forward-looking statements, such as expected financial results, medical benefits, regulatory milestones and commercial potential of Soliris, asfotase alfa and our other product candidates globally; plans for development and clinical trials of Soliris, asfotase alfa and our other product candidates; and operations reimbursement, price approval and funding processes in different countries.

Forward-looking statements are subject to factors that may cause our results and plans to differ from those expected, including decisions of regulatory authorities regarding approval or limitations on the marketing of Soliris and our product candidates for various indications; the possibility that results of clinical trials are not predictive of the safety and efficacy of Soliris or our product candidates from broader patient populations in the disease studied or in other diseases; the risk that third parties won’t agree to license any necessary intellectual property to us on reasonable terms or at all; the possibility that initial results of commercialization are not predictive of future results; the risk that third party payers will not or will not continue to reimburse for the use of Soliris at acceptable rates or at all; and a variety of other risks set forth from time to time in our filings with the SEC, including our 10-Q for the three months March 31, 2012.

We do not intend to update any of these forward-looking statements after this call, except when the duty arises under law.

I’d like to remind you that our reported non-GAAP numbers conform to US GAAP except in three respects. First, our non-GAAP numbers exclude share-based compensation. Second, we adjust for tax items associated with utilization of our US net operating losses and the Q2 tax expense related to acquisition structuring. And third, we also exclude costs associated with acquisitions. A reconciliation of our GAAP to non-GAAP results is included in the press release we issued this morning.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk